DexCom price target raised to $103 from $99 at Canaccord

Canaccord analyst William Plovanic raised the firm’s price target on DexCom (DXCM) to $103 from $99 and keeps a Buy rating on the shares. The firm said both US and OUS revenues were ahead of estimates from prior to the preannouncement, with US revenue growing as the company’s realigned salesforce continues to improve its productivity following the turmoil of the Q2/24 miss.